Foghorn Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $9,247 | $8,153 | $7,557 | $5,952 |
Gross Profit | 8,445 | -11,849 | 6,657 | 5,952 |
EBITDA | -18,794 | -14,997 | -17,036 | -22,086 |
EBIT | -19,596 | -15,849 | -17,936 | -22,913 |
Net Income | -21,664 | -15,849 | -17,936 | -18,834 |
Net Change In Cash | 9,247 | 8,153 | 7,557 | 5,952 |
Free Cash Flow | -22,271 | -18,860 | -21,022 | -23,996 |
Cash | 80,876 | 89,334 | 72,572 | 61,026 |
Basic Shares | 62,980 | 63,029 | 62,978 | 62,848 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $30,909 | $22,602 | $34,155 | $19,228 |
Gross Profit | 27,577 | 22,602 | 34,155 | 19,208 |
EBITDA | -78,775 | -97,165 | -104,455 | -113,816 |
EBIT | -82,107 | -100,285 | -107,906 | -117,137 |
Net Income | -74,283 | -86,620 | -98,426 | -108,873 |
Net Change In Cash | 30,909 | 22,602 | 34,155 | 19,228 |
Cost of Revenue | -48,947 | |||
Free Cash Flow | -86,149 | -101,312 | -119,330 | 192,402 |
Cash | 80,876 | 55,454 | 80,336 | 52,214 |
Basic Shares | 62,980 | 54,899 | 41,974 | 41,591 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | -$0.36 |
2025-09-30 | -$0.25 |
2025-06-30 | -$0.28 |
2025-03-31 | -$0.30 |
